Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.

J Pharmacokinet Pharmacodyn · 2021 · PMC8225544 · PMID 33728546

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with higher body weight showed a trend towards higher cemiplimab exposure with the weight-based 3 mg/kg Q2W dose regimen; the trend was reversed for the fixed 350 mg Q3W dose regimen (Table 4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.